Molecular classification and therapeutics in diffuse large B-cell lymphoma
Authors:
Open Access
- 3 February 2023
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 10, 1124360
Abstract
Diffuse large B-cell lymphoma (DLBCL) encompasses a wide variety of disease states that have to date been subgrouped and characterized based on immunohistochemical methods, which provide limited prognostic value to clinicians and no alteration in treatment regimen. The addition of rituximab to CHOP therapy was the last leap forward in terms of treatment, but regimens currently follow a standardized course when disease becomes refractory with no individualization based on genotype. Research groups are tentatively proposing new strategies for categorizing DLBCL based on genetic abnormalities that are frequently found together to better predict disease course following dysregulation of specific pathways and to deliver targeted treatment. Novel algorithms in combination with next-generation sequencing techniques have identified between 4 and 7 subgroups of DLBCL, depending on the research team, with potentially significant and actionable genetic alterations. Various drugs aimed at pathways including BCR signaling, NF-κB dysfunction, and epigenetic regulation have shown promise in their respective groups and may show initial utility as second or third line therapies to patients with recurrent DLBCL. Implementation of subgroups will allow collection of necessary data to determine which groups are significant, which treatments may be indicated, and will provide better insight to clinicians and patients on specific disease course.Keywords
Funding Information
- National Institute of Dental and Craniofacial Research
- Feist-Weiller Cancer Center
- Louisiana State University
This publication has 190 references indexed in Scilit:
- MYC on the Path to CancerCell, 2012
- Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell LymphomaCancer Cell, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinementNature Immunology, 2011
- Inactivating mutations of acetyltransferase genes in B-cell lymphomaNature, 2011
- BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell LymphomaCancer Cell, 2010
- p53 post-translational modification: deregulated in tumorigenesisTrends in Molecular Medicine, 2010
- Oncogenic CARD11 Mutations Induce Hyperactive Signaling by Disrupting Autoinhibition by the PKC-Responsive Inhibitory DomainBiochemistry, 2010
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphomaNature, 2010
- BLAT—The BLAST-Like Alignment ToolGenome Research, 2002